Transthyretin Y78F Variant Monomers

Transthyretin Y78F Variant Monomers

• Background: Transthyretin is a transport protein in the serum and cerebospinal fluid that carried the thyroid hormone Thyroxine and retinol-binding protein bound to retinol. TTR misfolding and aggregation is known to be associated with the amyloiddiseases SSA, FAP and FAC (1-5). TTR is also thought to have beneficial side effects, such as binding to beta-amyloid protein, preventing beta-amyloid from accumulating into the plaques associated with Alzheimer's Disease (6). The mutant variant Y78F indicates a destabilization of the contacts between the alpha-helix and AB loop and the body of the molecule, potentially leading to applications in immne therapy for FAP (7).
• Description: Human Recombinant Transthyretin Y78F Variant Protein Monomers
• Product Name Alternative: Amyloid polyneuropathy Protein Monomer, Amyloidosis I Protein Monomer, ATTR Protein Monomer, Carpal tunnel syndrome 1 Protein Monomer, CTS Protein Monomer, CTS1 Protein Monomer,= HEL111 Protein Monomer, HsT2651 Protein Monomer, PALB Protein Monomer, Prealbumin Protein Monomer, Prealbumin amyloidosis type I Protein Monomer, Prealbumin Thyroxine-binding Protein Monomer, TBPA Protein Monomer, Thyroxine binding prealbumin Protein Monomer, Transthyretin Protein Monomer, TTHY_HUMAN Protein Monomer,TTR Protein Monomer, TTR protein
• UNSPSC: 12352202
• Gene ID: 7276
• Swiss Prot: P02766
• Accession Number: NP_000362.1
• Cellular Locus: Cytoplasm | Extracellular exosome | Extracellular Region | Lysosome
• Host: E. coli
• Origin Species: Human
• Target: Transthyretin (TTR)
• Conjugation: No tag
• Sequence: MGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSFWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE
• Applications: WB, SDS-PAGE, In vivo assay, In vitro assay
• Purification Method: Ion-exchange Purified
• Concentration: Lot/batch specific. See included datasheet.
• Purity: >95%
• Weight: 0.2
• Length: Full length
• Buffer: PBS pH 7.4
• Molecular Weight: 13.876 kDa
• Precautions: Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.
• Additionnal Information: For corresponding PFFs, see catalog# SPR-465
• References & Citations: 1. Zeldenrust S.R., Benson M.D. (2010). Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990). Proc. Natl. Acad. Sci. U.S.A. 87(7): 2843–5. 3. Andrade C. (1952). Brain. 75(3): 408–27. 4. Coelho T. (1996). Curr. Opin. Neurol. 9(5): 355–9. 5. Jacobson D.R, et. al. (1997). N. Engl. J. Med. 336(7): 466–73. 6. Li X. (2011). Mol Neurodegener. 6(1):79. 7. Terazaki H.,m et al. (2006) Lab Invest. 86(1): 23-31.